Key Takeaways
- • ClearNote Health closed $52 million in Series D financing, bringing total capital raised to more than $185 million from institutional investors.
- • The round was led by founding investor Mattias Westman and a global large-cap active manager, with participation from former Citigroup chairman Sandy Weill and Stanford co-founder Dr. Stephen Quake.
- • Kevin Keegan, an industry veteran, was appointed president and chief operating officer to lead operational expansion and accelerate growth.
- • The capital infusion positions the company to scale noninvasive early cancer detection tools across markets with increasing demand for accurate, accessible, and affordable diagnostic solutions.
- • Investor base includes a large Seattle-based family office alongside U.S. and international institutional investors, reflecting broad confidence in the early detection market.
Summary
ClearNote Health, a San Diego-based oncology diagnostics company, announced the closure of $52 million in Series D financing on May 28, 2026. The round brings the company's total funding to more than $185 million, signaling sustained institutional confidence in its early cancer detection platform. The financing was led by founding investor Mattias Westman and a global, large, long-only active manager, with notable participation from former Citigroup chairman and CEO Sandy Weill, reflecting both established venture backing and blue-chip financial sector validation.
The round also included ClearNote Health co-founder Dr. Stephen Quake of Stanford University alongside a large Seattle-based family office and additional U.S. and international institutional investors. This diversified investor base underscores the market opportunity in noninvasive cancer detection tools, which address a critical gap in early diagnosis for some of the highest-mortality cancer types.
Concurrent with the financing announcement, ClearNote Health appointed Kevin Keegan as president and chief operating officer. Keegan's hiring represents a significant operational milestone, bringing industry-tested leadership to accelerate the company's growth trajectory. The company frames this dual announcement—capital infusion plus executive leadership—as strategic positioning to meet escalating demand for more accurate, accessible, and affordable diagnostic alternatives to traditional invasive screening methods.
The $52 million Series D reflects broader investor momentum in precision oncology and early detection, a segment gaining traction as healthcare systems prioritize cost-effective, patient-friendly diagnostic pathways. ClearNote's institutional backing from both active managers and prominent individual investors suggests confidence in the commercial viability and clinical validation of its technology platform.
The round also included ClearNote Health co-founder Dr. Stephen Quake of Stanford University alongside a large Seattle-based family office and additional U.S. and international institutional investors. This diversified investor base underscores the market opportunity in noninvasive cancer detection tools, which address a critical gap in early diagnosis for some of the highest-mortality cancer types.
Concurrent with the financing announcement, ClearNote Health appointed Kevin Keegan as president and chief operating officer. Keegan's hiring represents a significant operational milestone, bringing industry-tested leadership to accelerate the company's growth trajectory. The company frames this dual announcement—capital infusion plus executive leadership—as strategic positioning to meet escalating demand for more accurate, accessible, and affordable diagnostic alternatives to traditional invasive screening methods.
The $52 million Series D reflects broader investor momentum in precision oncology and early detection, a segment gaining traction as healthcare systems prioritize cost-effective, patient-friendly diagnostic pathways. ClearNote's institutional backing from both active managers and prominent individual investors suggests confidence in the commercial viability and clinical validation of its technology platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.